The latest report by IMARC Group, titled “Australia Medical Cannabis Market Size, Share, Trends and Forecast by Species, Derivatives, Application, Route of Administration, End Use, and Region, 2025-2033,” offers a comprehensive analysis of the Australia medical cannabis market growth. The report also includes competitor and regional analysis, along with a breakdown of segments within the industry. The Australia medical cannabis market size reached USD 740.0 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,373.1 Million by 2033, exhibiting a growth rate (CAGR) of 7.10% during 2025–2033.
Report Attributes:
- Base Year: 2024
- Forecast Years: 2025–2033
- Historical Years: 2019–2024
- Market Size in 2024: USD 740.0 Million
- Market Forecast in 2033: USD 1,373.1 Million
- Market Growth Rate 2025–2033: 7.10%
For an in-depth analysis, you can refer to a sample copy of the report: https://www.imarcgroup.com/australia-medical-cannabis-market/requestsample
How Is AI Transforming the Medical Cannabis Industry in Australia?
- Precision dosing algorithms are revolutionizing patient care, with machine learning systems analyzing individual responses to cannabinoid treatments optimizing personalized medication regimens
- Predictive analytics are enhancing treatment outcomes, utilizing patient data patterns to forecast efficacy, side effects, and optimal cannabinoid ratios for specific medical conditions
- Automated cultivation management is improving product consistency, with AI-powered systems monitoring environmental conditions, nutrient levels, and growth cycles ensuring pharmaceutical-grade quality
- Natural language processing is streamlining prescriber education, with intelligent chatbots providing real-time guidance on product selection, dosing protocols, and regulatory compliance requirements
- Supply chain optimization technologies are reducing costs, employing machine learning to forecast demand patterns, minimize inventory waste, and improve distribution efficiency across pharmacy networks
Australia Medical Cannabis Market Overview
- Regulatory framework is strengthening market foundation, with TGA’s Special Access Scheme and Authorised Prescriber pathways enabling streamlined patient access to cannabis-based medicines
- Patient demand is expanding rapidly, with over 3 million Australians suffering chronic pain seeking alternative treatments beyond traditional pharmaceuticals with limited effectiveness
- Telehealth integration is democratizing access, with online clinics removing geographical barriers connecting patients with cannabis-aware prescribers across rural and underserved communities
- Product diversification is meeting varied needs, with market shifting from oil and capsule dominance toward dried flower, vaporizers, and topical applications offering faster therapeutic onset
- Domestic production is increasing significantly, with local cultivation facilities achieving GMP certification reducing import dependency and improving supply chain reliability
Key Features and Trends of Australia Medical Cannabis Market
- High-THC flower adoption is accelerating dramatically, with patients preferring vaporized cannabis for immediate relief from chronic pain, anxiety, and insomnia compared to slower-acting oral formats
- GMP-certified production is becoming industry standard, with pharmaceutical-grade manufacturing ensuring dosing consistency, safety verification, and regulatory compliance building prescriber confidence
- Telehealth platforms are expanding market reach, with digital clinics handling consultations, prescriptions, and product delivery creating seamless patient experiences without in-person visits
- Price reductions are improving accessibility, with increased competition and domestic production lowering average product costs making treatments affordable for broader patient populations
- Clinical research is advancing rapidly, with Australian universities and research centers conducting studies validating therapeutic efficacy across diverse medical conditions supporting prescriber adoption
Growth Drivers of Australia Medical Cannabis Market
- Rising Chronic Disease Prevalence: Over 3 million Australians suffering from chronic pain, anxiety, PTSD, epilepsy, and cancer-related symptoms are seeking alternative therapies with fewer side effects
- Government Regulatory Support: TGA’s progressive frameworks through Special Access Scheme and Authorised Prescriber pathways are streamlining approvals and encouraging physician prescribing behavior
- Telehealth Expansion: Online consultation platforms are eliminating traditional access barriers, particularly benefiting rural patients who lack access to cannabis-aware general practitioners
- Product Diversification: Expanding offerings including dried flower, oils, capsules, vaporizers, and topicals are meeting diverse patient preferences and condition-specific treatment requirements
- Domestic Production Growth: Increasing local cultivation with GMP certification is reducing import dependency, lowering costs, and ensuring consistent pharmaceutical-grade product supply
Innovation & Market Demand of Australia Medical Cannabis Market
- Strain-specific formulations are addressing targeted conditions, with cultivators developing cannabinoid profiles optimized for sleep disorders, pain management, anxiety relief, and neurological conditions
- Microdosing protocols are gaining clinical acceptance, enabling patients to achieve therapeutic benefits with minimal psychoactive effects through precise low-dose cannabinoid administration
- Sustained-release technologies are improving convenience, with extended-release capsules and patches providing consistent cannabinoid levels throughout day reducing dosing frequency requirements
- Pediatric formulations are emerging carefully, with CBD-dominant products for treatment-resistant epilepsy undergoing rigorous clinical evaluation ensuring child-appropriate safety profiles
- Combination therapies are being explored extensively, investigating synergies between cannabinoids and conventional pharmaceuticals for enhanced efficacy in complex medical conditions
Australia Medical Cannabis Market Opportunities
- International export development presents substantial growth potential, with Australia’s GMP-certified production capabilities positioning country as reliable supplier for emerging medicinal cannabis markets
- Palliative care integration offers humanitarian impact, with end-of-life symptom management including pain, nausea, and appetite stimulation representing compassionate care expansion opportunity
- Veterinary medicine applications are emerging gradually, with preliminary research indicating potential therapeutic benefits for companion animals creating entirely new market segment
- Workplace policy evolution creates professional adoption, as corporate acceptance and occupational health frameworks adapt to accommodate medicinal cannabis use among employees
- Private health insurance coverage expansion would accelerate accessibility, with inclusion in pharmaceutical benefits schemes reducing out-of-pocket expenses encouraging broader patient adoption
Australia Medical Cannabis Market Challenges
- Prescription pathway complexity constrains accessibility, with many general practitioners lacking training, confidence, or willingness to prescribe cannabis-based medicines limiting patient reach
- Product cost barriers persist significantly, with medicinal cannabis treatments typically costing AUD 200-500 monthly creating affordability challenges for low-income patients with chronic conditions
- Clinical evidence gaps affect prescriber confidence, with limited long-term safety data and double-blind clinical trials creating hesitation among conservative medical practitioners
- Stigma and misconceptions remain prevalent, with lingering negative perceptions about cannabis use deterring some patients from exploring legitimate therapeutic applications despite medical recommendations
- Supply chain inconsistencies create frustrations, with periodic product shortages, import delays, and batch variability affecting treatment continuity and patient satisfaction levels
Australia Medical Cannabis Market Analysis
- Market segmentation reveals hybrid strains commanding largest share, combining balanced THC-CBD ratios appealing to patients seeking therapeutic benefits with manageable psychoactive effects
- Derivatives distribution shows CBD products leading medical applications, though THC-dominant formulations are growing rapidly as prescriber comfort with psychoactive cannabinoids increases
- Application analysis indicates chronic pain representing primary use case with 40% market share, followed by mental health conditions, neurological disorders, and cancer-related symptom management
- Route of administration patterns show oral solutions and capsules maintaining majority share, while vaporizer adoption accelerates driven by patient preference for fast-acting relief
- Regional concentration shows New South Wales and Victoria accounting for over 60% of prescriptions, reflecting higher physician awareness and patient population density
Australia Medical Cannabis Market Segmentation:
- By Species:
- Indica
- Sativa
- Hybrid
- By Derivatives:
- Cannabidiol (CBD)
- Tetrahydrocannabinol (THC)
- Others
- By Application:
- Cancer
- Arthritis
- Migraine
- Epilepsy
- Others
- By Route of Administration:
- Oral Solutions and Capsules
- Vaporizers
- Topicals
- Others
- By End Use:
- Pharmaceutical Industry
- Research and Development Centers
- Others
- By Region:
- Australia Capital Territory & New South Wales
- Victoria & Tasmania
- Queensland
- Northern Territory & Southern Australia
- Western Australia
Australia Medical Cannabis Market News & Recent Developments:
February 2025: Dispensed, a leading Australian medicinal cannabis company, announced plans to launch New Zealand operations utilizing kiosks in pharmacies and clinics, marking international expansion leveraging telehealth platform success.
September 2024: Tilray Medical, division of Tilray Brands Inc., introduced Redecan EU-GMP-certified medical cannabis products in Australia, expanding patient and healthcare professional access to internationally-recognized therapeutic cannabis formulations.
2024: Australian medical cannabis patient numbers surpassed 300,000 active prescriptions, representing substantial growth from initial regulatory framework implementation in 2016, demonstrating increasing physician and patient acceptance.
2024: Dried flower prescriptions increased significantly, with high-THC strains gaining market share as patients and prescribers recognize faster therapeutic onset compared to oral administration formats.
Australia Medical Cannabis Market Key Players:
- Cannatrek
- Little Green Pharma
- Medcan Australia
- Cann Group Limited
- Althea Group Holdings
- Tilray Medical Australia
- Spectrum Therapeutics (Canopy Growth)
- MGC Pharmaceuticals
- Ecofibre Limited
- THC Global Group
- Cronos Australia
- Dispensed
- Alternaleaf
- Montu Group
- Australian Natural Therapeutics Group
Key Highlights of the Report:
- Market Performance (2019–2024)
- Market Outlook (2025–2033)
- COVID-19 Impact on the Market
- Porter’s Five Forces Analysis
- Strategic Recommendations
- Historical, Current and Future Market Trends
- Market Drivers and Success Factors
- SWOT Analysis
- Structure of the Market
- Value Chain Analysis
- Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
Ask analyst for your customized sample:
https://www.imarcgroup.com/request?type=report&id=32011&flag=E
Conclusion of Report:
- Australia’s medical cannabis market is experiencing robust transformation driven by progressive regulatory frameworks, expanding patient numbers surpassing 300,000 prescriptions, and growing physician acceptance across medical specialties
- Product evolution from oil-dominant offerings toward diverse formats including high-THC flower, vaporizers, and topicals is meeting varied patient preferences while improving therapeutic outcomes
- Telehealth integration through platforms like Dispensed is democratizing access, eliminating traditional barriers, and creating seamless patient experiences from consultation through product delivery
- Domestic production capacity expansion with GMP-certified facilities is reducing import dependency, lowering costs, and ensuring pharmaceutical-grade quality supporting long-term market sustainability
- Market trajectory indicates near-doubling through 2033, supported by chronic disease prevalence exceeding 3 million potential patients, continued regulatory support, and advancing clinical research validating therapeutic efficacy
About Us:
IMARC Group is a leading market research company that provides management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our solutions include comprehensive market intelligence, custom consulting, and actionable insights to help organizations make informed decisions and achieve sustainable growth.
Contact Us:
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No: (D) +91 120 433 0800
United States: +1-201-971-6302
